

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

Learning from Longitudinal Data in Electronic Health Record and Genetic Data to Improve Cardiovascular Event Prediction

Juan Zhao, PHD¹; QiPing Feng, PHD²; Patrick Wu, BS¹; Roxana Lupu, MD³; Russell A. Wilke, MD³; Quinn S. Wells, MD⁴; Joshua C. Denny, MD, MS^{1,4}, Wei-Qi Wei, MD, PhD^{1*}

¹Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA

²Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA

³Department of Medicine, University of South Dakota Sanford School of Medicine, Sioux Falls, SD, USA

⁴Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

* Corresponding author

Email: wei-qi.wei@vanderbilt.edu

Department of Biomedical Informatics

2525 West End Ave., Suite 1500

Nashville, TN 37203

Tel: (615)343-1956

23 **ABSTRACT**

24 **Background:** Current approaches to predicting Cardiovascular disease rely on conventional risk
25 factors and cross-sectional data. In this study, we asked whether: i) machine learning and deep
26 learning models with longitudinal EHR information can improve the prediction of 10-year CVD
27 risk, and ii) incorporating genetic data can add values to predictability.

28 **Methods:** We conducted two experiments. In the first experiment, we modeled longitudinal
29 EHR data with aggregated features and temporal features. We applied logistic regression (LR),
30 random forests (RF) and gradient boosting trees (GBT) and Convolutional Neural Networks
31 (CNN) and Recurrent Neural Networks, using Long Short-Term Memory (LSTM) units. In the
32 second experiment, we proposed a late-fusion framework to incorporate genetic features.

33 **Results:** Our study cohort included 109,490 individuals (9,824 were cases and 99,666 were
34 controls) from Vanderbilt University Medical Center's (VUMC) de-identified EHRs. American
35 College of Cardiology and the American Heart Association (ACC/AHA) Pooled Cohort Risk
36 Equations had areas under receiver operating characteristic curves (AUROC) of 0.732 and areas
37 under receiver under precision and recall curves (AUPRC) of 0.187. LSTM, CNN and GBT with
38 temporal features achieved best results, which had AUROC of 0.789, 0.790, and 0.791, and
39 AUPRC of 0.282, 0.280 and 0.285, respectively. The late fusion approach achieved a significant
40 improvement for the prediction performance.

41 **Conclusions:** Machine learning and deep learning with longitudinal features improved the 10-
42 year CVD risk prediction. Incorporating genetic features further enhanced 10-year CVD

43 prediction performance, underscoring the importance of integrating relevant genetic data
44 whenever available in the context of routine care.

45 **Key words:** cardiovascular disease prediction, machine learning, deep learning, genetics,
46 electronic health records

47 **INTRODUCTION**

48 Cardiovascular disease (CVD) is the leading cause of morbidity and mortality,
49 accounting for one-third of all global deaths [1,2]. There have been several proposed several
50 prediction models, including the Framingham risk score [3], American College of
51 Cardiology/American Heart Association (ACC/AHA) Pooled Cohort Risk Equations [4], and
52 QRISK2 [5]. These models are typically built upon a combination of readily-available cross-
53 sectional risk factors such as hypertension, diabetes, cholesterol, age, and smoking status.
54 Although the importance of conventional models cannot be ignored, well-known clinical risk
55 factors for CVD explain only 50-75% of the variance in major adverse cardiovascular events [6].
56 About 15%-20% of patients who experienced myocardial infarctions had only one or two of
57 these traditional risk factors and were not identified as being at “risk” of CVD according to
58 current prediction models [7]. Given the fact that CVD is preventable, and that its first
59 manifestation may be fatal, a new strategy to enhance risk prediction beyond conventional
60 factors is critical for public health.

61 Electronic health records (EHRs) contain a wealth of detailed clinical information and
62 provide several distinct advantages for clinical research, including cost efficiency, a large
63 amount of data, and the ability to analyze data over time. Since its wide implementation in the

64 United States, accumulated EHR data has become an important resource for clinical studies. [8].
65 Meanwhile, the recent convergence of two rapidly developing technologies—high-throughput
66 genotyping and deep phenotyping within EHRs – presents an unprecedented opportunity to
67 utilize routine healthcare data and genetic information to accelerate the improvement of
68 healthcare. Many institutions and health care systems have been building EHR-linked DNA
69 biobanks to enable such a vision. For example, Vanderbilt University Medical Center (VUMC),
70 as of May 2018, has genotype data of over 50,000 individuals available for research.

71 Machine learning and deep learning approaches are particularly suited to the integration
72 of big data, such as the data available within EHRs, especially when the EHR contains genetic
73 information [9,10]. A recent study from the United Kingdom (UK) applied machine learning on
74 conventional CVD risk factors from a large UK population and improved the overall prediction
75 performance by 4.9% [11]. In the current study, we examined: i) the performance of machine
76 learning and deep learning on longitudinal EHR data for the prediction of 10-year CVD risk, and
77 ii) the benefits of incorporating extra genetic information.

78 **METHODS**

79 **Study setting**

80 We conducted the study using data derived from Synthetic Derivative, a de-identified
81 copy of whole EHRs at VUMC. Synthetic Derivative maintains rich and longitudinal EHR data
82 from over 3 million unique individuals, including demographic details, physical measurements,
83 history of diagnosis, prescription drugs, and laboratory test results. As of May 2018, over 50,000
84 of these individuals have genotype data available.

85 We focused our analysis on individuals with European or African ancestry. We required
86 individuals to meet the definitions of medical home [12]. We set the baseline date as 01/01/2007
87 to allow all individuals within the cohort to be followed-up for 10 years. For each individual, we
88 split the EHR into: i) the observation window (01/01/2000 to 12/31/2006; 7 years) and, ii) the
89 prediction window (01/01/2007 to 12/31/2016; 10 years). We extracted EHR data within the 7-
90 year observation window to train a predictive model to predict CVD event occurred in prediction
91 window.

92 Cases were individuals with ≥ 1 CVD diagnosis codes (the International Classification of
93 Diseases, Ninth Revision, Clinical Modification [ICD-9-CM]: 411. * and 433. *) recorded within
94 the 10-year prediction window. Controls were individuals without any ICD-9-CM code 411. * or
95 433. * during the 10-year prediction window.

96 **Study cohort**

97 The study cohort included patients between the ages of 18 to 78 on 01/01/2000
98 (beginning of the observation window). Individuals with any CVD diagnosis (ICD-9-CM 411. *
99 or 433. *) prior to the baseline date for the prediction window (i.e. 01/01/2007) were excluded.
100 To reduce chart fragmentation and optimize the density of our longitudinal EHR data, we
101 required that each individual to have at least one visit and at least one record of blood pressure
102 measurement during the observation window [13,14]. We excluded inpatient physical or
103 laboratory measures for all individuals.

104 In total, we identified 109, 490 individuals (9,824 cases and 99, 666 controls, mean [SD]
105 age 47.4 [14.7] years; 64.5% female and 86.3% European) as our main study cohort. The

106 case/control ratio was consistent with a previous report from a large EHR cohort [11]. Among
107 these 109,490 individuals, a subset of 10,162 individuals (2,452 cases and 7,710 controls) had
108 genotype data available.

109 **Data preprocessing and feature extraction**

110 Phenotypic data: we extracted features including demographics, variables used in the
111 ACC/AHA Pooled Cohort Risk Equations (ACC/AHA Equations) (e.g. blood pressure
112 measurements), physical measurements including BMI, and laboratory measures including
113 glucose, triglyceride levels, and creatinine level (as a marker of renal function); such laboratory
114 features have previously been reported relevant to CVD [11]. In addition, we applied chi-square
115 (χ^2) [15], a commonly used feature selection methods that can select independent features on
116 EHR data and identified an additional 40 relevant diagnostic codes and medication codes (Table
117 1). Values for all features were extracted within the observation window.

118 We represented a physical measurement or laboratory feature with summarized data, e.g.
119 minimum, maximum, median, and standard deviation (SD). We removed the outliers (>5 SD
120 from the mean) to avoid unintended incorrect measurements (e.g. using lb. instead of kg. for
121 body weight) [16]. If an individual had no such measure available within the EHR, we imputed
122 the missing value with the median value of the group with the same age and gender [17]. We
123 also added a dummy variable for each measure to indicate whether the test value was imputed.

124 For disease phenotypes, we followed a standard approach and grouped relevant ICD
125 codes into distinct phecodes [19]. For medications, we collapsed brand names and generic names
126 into groups by their composition (ingredients) and represented the groups using the RxNorm [19]

127 concepts (RxCUIs) for this variable. For example, ‘Tylenol Caplet, 325 mg oral tablet’ and
128 ‘Tylenol Caplet, 500 mg oral tablet’ were both mapped to ‘Acetaminophen’ (RxCUI 161). We
129 used a binary value to indicate whether or not an individual had each diagnosis or prescription.

130 For genetic data, we selected 248 single nucleotide polymorphisms (SNPs) that have
131 been previously reported to be associated with CVD in two large meta-analyses [20,21]. Among
132 these SNPs, genotype data were available for 204 SNPs in our cohort and were included as
133 features. Each SNP had a value 0, 1, or 2 based on the count of minor alleles for an individual.
134 Table 1 shows the features that we used in the machine learning models.

135 **Table 1. Features included in the machine-learning models.**

Feature type	Features	Values
Demographic	Age*	Continuous
	Gender*	Binary
	Race	Categorical
Life styles	Body mass index (BMI)	Summarized data†
	Smoking*	Binary
Physical or lab measurements	Systolic blood pressure (SBP)*	Summarized data†
	Diastolic blood pressure (DBP)*	Summarized data†
	Total Cholesterol (Cholesterol)*	Summarized data†

	HDL Cholesterol (HDL-C)*	Summarized data†
	LDL Cholesterol (LDL-C)	Summarized data†
	Creatinine	Summarized data†
	Glucose	Summarized data†
	Triglyceride	Summarized data†
Diagnosis	Other tests (phecode 1010)	Binary
	Benign neoplasm of skin (216)	
	Diabetes mellitus* (250)	
	Disorders of lipid metabolism (272)	
	Other mental disorder, random mental disorder (306)	
	Heart valve disorders (395)	
	Hypertension (401)	
	Cardiomyopathy (425)	
	Congestive heart failure; nonhypertensive (428)	
	Atherosclerosis (440)	
Acute upper respiratory infections of multiple or unspecified sites (465)		

	Chronic airway obstruction (496)	
	Disorders of menstruation and other abnormal bleeding from female genital tract (626)	
Medication	Warfarin (RXCUI 11289)	Binary
	Aspirin (1191)	
	Atenolol (1202)	
	Amlodipine (17767)	
	Carvedilol (20352)	
	Lisinopril(29046)	
	Adenosine(296)	
	Clopidogrel (32968)	
	Digoxin (3407)	
	Diltiazem (3443)	
	Ramipril (35296)	
	Diuretics (3567)	
	Dobutamine (3616)	
Simvastatin(36567)		

	Enalapril (3827)	
	Sestamibi (408081)	
	Ethinyl Estradiol (4124)	
	Furosemide (4603)	
	Nitroglycerin (4917)	
	Hydrochlorothiazide(5487)	
	Ibuprofen (5640)	
	Metoprolol (6918)	
	Acellular pertussis vaccine (798302)	
	Atorvastatin(83367)	
	ACE inhibitors (836)	
	Thallium(1311633)	
	Clonidine (2599)	
Genetic	204 SNPs [#]	Categorical
Others	EHR length	Continuous

*Features in ACC/AHA Equations

† Summarized data includes minimum, maximum, median and SD within a time window.

204 SNPs are listed in the Supplementary Appendices S1

136

137 **Experiment**

138 *Gold standard.* We chose ACC/AHA Pooled Cohort Risk Equations for 10-year CVD
139 risk as our baseline. For physical measurements or laboratory features (i.e. SBP/DBP and high-
140 density lipoprotein [HDL]- cholesterol level), we used the most recent values prior to the split
141 date, 01/01/2007.

142 **Machine learning and deep learning with longitudinal EHR data to predict**
143 **10-year CVD risk (Experiment I)**

144 The objective of this experiment is to examine 1) predictive performance achieved by
145 machine learning and deep learning with longitudinal EHR data compared to golds standard, and
146 2) two different approaches we use to model the longitudinal EHR data for machine learning
147 models (Figure 1).

148 *Aggregate features.* We aggregated features across the 7-year observation window (e.g.
149 median, max, min and SD of HDL from 01/01/2000 to 12/31/2006).

150 *Multivariate temporal features.* We exploited the temporal information in the
151 longitudinal EHR data by dividing the whole observation window into one-year slice window.
152 Specifically, for physical or laboratory features, we extracted the median, max, min and SD
153 values within one-year slice window. We replaced the missing physical or laboratory measures
154 with the individual's measurement on the closest date, e.g. using the HDL cholesterol result on

155 12/20/2005 instead if the individual had no HDL test in 2006. For diagnosis and medication
156 features, we used a binary value to indicate whether or not an individual had each diagnosis or
157 prescription in one-year slice window.

158 *Machine learning and deep learning models.* Three machine learning models, LR, RF
159 and GBT were used in both aggregate and temporal features. Two deep learning models,
160 Convolutional Neural Networks (CNN) [22] and Recurrent Neural Networks, using Long Short-
161 Term Memory (LSTM) hidden units (LSTM) [23]) were applied to the temporal features. We
162 compared their performance with the gold standard.

163 *Implementation detail:* We used CNN and LSTM on temporal features and concatenated
164 an auxiliary input of demographic features to feed into a multilayer perceptron (MLP) with two
165 hidden layers. More details can be found in Supplementary Appendices S2. LR, RF, and GBT
166 models were implemented with Python Scikit-Learn 0.19.1 (<http://scikit-learn.org/stable/>) [24].
167 The CNN and LSTM models were implemented with Keras 2.1.3 (<https://keras.io/>) using
168 Tensorflow1.6.1 as the backend.

169 *Evaluation.* We divided the dataset into a training and a test set with a 90/10 split and
170 learned the models with a 10-fold stratified cross- validation using grid search on the training set.
171 Finally, we evaluated the optimized model on the test set using area under a receiver operating
172 characteristic curve (AUROC) and average precision, also known as area under precision-recall
173 curve (AUPRC) [25]. For each machine learning model, we repeated the above processed 10
174 times. For deep learning models, we randomly divided the data into training, validation, and
175 testing sets with a ratio of 8:1:1 and iterated the process for 10 times. We reported the mean and
176 SD of AUROC and AUPRC.

177 Machine learning and deep learning with additional genetic information to
178 predict 10-year CVD risk. (Experiment II)

179 The objective of this experiment is to examine combining genetic features with
180 demographic and longitudinal EHR data compared to only using demographic and longitudinal
181 EHR data for 10- year CVD prediction. To meet the objectives, we used a subset of 10,162 had
182 genotyped data from the main study cohort of 109, 490 individuals. It is also a subset of BioVU
183 (VUMC's de-identified DNA biobank) that contains nearly >50,000 genotyped individuals.

184 We developed a two-stage framework of using late-fusion approach to incorporate EHR
185 and genotyped features. Late-fusion is an effective approach to enhance prediction accuracy by
186 combining the prediction results of multiple models trained separately by a group of features. [26]
187 Here, we trained two machine learning models separately by EHR data and genotyped data and
188 used a subset of 10,162 which had both available EHR and genotyped data to train and test a
189 fusion model based on the prediction results. (Figure 2 and 3). The subset of 10,162 individuals
190 (intersect cohort) was randomly split into a training set (8,129 individuals) and a holdout test set
191 (2, 033 individuals) with an 80/20 split. The training set is used for training the fusion model at
192 final decision level. The holdout test set is used for comparing the performance of models trained
193 with only EHR data and the proposed late-fusion approach.

194 In the first stage of the framework, we trained a machine learning model (model1) with
195 longitudinal EHR features on the main study cohort (removing holdout test set). We trained
196 another machine learning model (model 2) with 204 SNPs features on a big 34,926 genotyped
197 cohort (removing holdout test set), which shared similar criteria with the main study cohort
198 except for not restricting to the criteria for having >1 record of SBP in the observation window.

199 In the second stage, we combined the predictions scores of two models on the training set (8, 129
200 individuals) to train a late fusion model. We used gradient boosting trees for the model 1 because
201 it has good generalizability as an ensemble approach to make it more robust. We used the
202 logistic regression as model 2 and the late fusion model.

203 To compare the performance of adding genetic features, we evaluated prediction
204 performance of model 1 and fusion model on the holdout test set (2,033 individuals). We
205 performed 5-fold cross-validation and repeated the process 10 times. We reported the mean and
206 SD of AUROC and AUPRC.

207 **RESULTS**

208 **Machine learning and deep learning models with longitudinal EHR data to** 209 **predict 10-year CVD risk (Experiment I)**

210 Table 2 shows the results for the experiment. The performance of the gold standard
211 (AUROC 0.732, AUPRC 0.187) was consistent with other study reports [11,27]. Compared with
212 gold standard, all three machine-learning models with aggregate features achieved significant
213 improvements over the prediction metrics. For AUROC, RF increased the performance from
214 0.732 to 0.765, an absolute (relative) improvement of +0.033 (+4.5%). LR [+0.044 (+ 6.0%)]
215 and GBT [+0.05 (+6.8%)] had a higher increase rate. For AUPRC, the improvement was much
216 bigger, from RF [0.059 (+31.6%)] to GBT [+ 0.081 (+43.3%)].

217 **Table 2. Performance of machine learning and deep learning models predicting 10-year**
218 **CVD risk. The + indicates that the mean is significantly different from the mean of gold**
219 **standard ($p < 0.05$), when evaluated using the t -test. # indicates that the mean of the model**

220 **on longitudinal one-year slice window is significantly different from the model with**
 221 **aggregate features.**

Method	AUROC	AUPRC
ACC/AHA Equations	0.732 (\pm 0.010)	0.187 (\pm 0.009)
Machine learning models on aggregate features across seven-year window		
Logistic regression (LR)	0.776 (\pm 0.008) ⁺	0.260 (\pm 0.014) ⁺
Random forest (RF)	0.765 (\pm 0.009) ⁺	0.246 (\pm 0.009) ⁺
Gradient boosting trees (GBT)	0.782 (\pm 0.009) ⁺	0.268 (\pm 0.014) ⁺
Machine learning models on longitudinal features within one-year window (temporal)		
Logistic regression (LR)	0.781 (\pm 0.007) ⁺	0.273 (\pm 0.013) ^{+#}
Random forest (RF)	0.753 (\pm 0.008) ⁺	0.236 (\pm 0.010) ⁺
Gradient boosting trees (GBT)	0.791 (\pm 0.008) ^{+#}	0.285 (\pm 0.013) ^{+#}
Deep learning models on longitudinal features within one-year window (temporal)		
LSTM	0.789 (\pm 0.011) ⁺	0.282 (\pm 0.012) ⁺
CNN	0.790 (\pm 0.012) ⁺	0.280 (\pm 0.012) ⁺

222 Compared to the aggregate features, using longitudinal features further improved the
 223 prediction performance across most models. AUROC of GBT is improved from 0.782 to 0.791

224 [+ 0.009 (+1.2%)] and the AUPRC of GBT is improved from 0.268 to 0.285 [+0.017; (+6.3%)].
225 LR [+0.0013 (5.0%)] also had a significant improvement in AUPRC. For deep learning models
226 with longitudinal features, LSTM and CNN achieved nearly same results as GBT, better than the
227 LR and RF. Overall, the best result achieved by GBT using longitudinal features increased the
228 AUROC of gold standard +0.059 (+8.1%) and AUPRC +0.098 (+52.4%).

229 *Feature importance.* We listed top features for each of optimized machine learning
230 models in Table 3. Feature importance was determined by the coefficient effect size from the LR
231 model. For RF and GBT, which are based on decision-trees, the features are ranked according to
232 the impurity (information gain/entropy) decreasing from each feature. Since CNN and LSTM are
233 black box models, estimation of each feature's contribution to predict CVD risk is difficult, so
234 we were not able to analyze the feature importance of the deep learning models in this study.

Table 3. Top 10 features for machine learning prediction in descending order of coefficient effect size or feature importance returned by RF and GBT. Systolic Blood Pressure (SBP); Diastolic Blood Pressure (DBP).

LR with aggregate features	RF with aggregate features	GBT with aggregate features	LR with longitudinal features	RF with longitudinal features	GBT with longitudinal features
EHR length	EHR length	Age	EHR length	EHR length	Age
Max LDL-C	Age	EHR length	Age	Age	EHR length
Min Creatinine	Max BMI	SD Creatinine	SD Glucose in 2000	Aspirin in 2006	Smoking
Age	Min BMI	Smoking	SD Creatinine in 2000	Max SBP in 2006	Heart valve disorders in 2006
Max HDL-C	Median BMI	Min BMI	Max HDL-C 2005	Min BMI in 2006	Hypertension in 2006
Max BMI	Max SBP	Heart valve disorders (Phecode 395)	SD Glucose in 2006	Median BMI in 2005	Aspirin in 2006
Max Cholesterol	Median SBP	Min Glucose	Median LDL-C in 2006	Median SBP in 2006	Disorders of lipid metabolism in 2006
Max DBP	SD BMI	Max SBP	Median BMI in 2006	Max BMI in 2006	Clopidogrel in 2006
Median Trigs	MIN SBP	Max Trigs	Median Cholesterol in 2006	Min BMI in 2001	Max SBP in 2006
Min Cholesterol	Max DBP	Aspirin	Heart valve disorders in 2006	Min BMI in 2002	SD Glucose in 2006

1 The conventional risk factors such as age, blood pressure and total cholesterol were
2 consistently present as top 10 features in all three machine learning models. BMI, Creatinine
3 and Glucose that were not in ACC/AHA equations were determined as important features in
4 machine learning models. Moreover, the maximum, minimum, and SD of laboratory values
5 showed promising contributions to the models. GBT models preferred diagnoses such as heart
6 valve disorder, hypertension, and lipid disorders over other features.

7 For machine learning models with longitudinal features, LR models selected laboratory
8 values in the years 2000 and 2006 (e.g. SD Glucose in 2000 and 2006). The RF models chose
9 BMI in multiple years. Whereas GBT models prioritized the medical conditions in the most
10 recent year (year 2006) in the observation window.

11 **Evaluate incorporating genetic features for machine learning models to** 12 **predict 10-year CVD risk (Experiment II)**

13 Table 4 reported the results of Experiment II. GBT with only longitudinal EHR features
14 improved AUROC of gold standard from 0.698 to 0.710 [+0.012 (+1.7%)] and AUPRC from
15 0.396 to 0.427 [+0.031(+7.8%)]. The proposed late fusion approach for adding genetic features
16 further improved the metrics, with AUROC +0.015 (+2.1%) and AUPRC +0.036 (+9.1%).

17 **Table 4. Comparison of predicting 10-year CVD risk with genetic features and**
18 **without genetic features. + indicates that the mean is significantly ($p < 0.05$) different from**
19 **gold standard, and # indicates that the mean is significantly different from GBT using**
20 **demographic and longitudinal EHR features, when evaluated using the paired *t*-test.**

Method	AUROC	AUPRC
ACC/AHA	0.698 (± 0.012)	0.396 (± 0.016)
Using demographic and longitudinal EHR features		
Gradient boosting trees (GBT)	0.710 (± 0.011) ⁺	0.427 (± 0.015) ⁺
Using demographic, longitudinal EHR and genetic features		
Fusion approach	0.713 (± 0.012) ^{+#}	0.432 (± 0.015) ^{+#}

21 We listed the top ten features in the pre-trained model with genetic data in Supplementary
22 Appendices S3. SNP (rs2789422) was ranked as the second most important feature after age.

23 **DISCUSSION**

24 Our results demonstrate that machine learning models with longitudinal EHR information
25 can improve the prediction of 10-year CVD risk. We also showed that incorporating genetic data
26 can enhance 10-year CVD risk prediction.

27 We used a large dataset including longitudinal EHR information of 109,490 individuals.
28 The prediction result of ACC/AHA (AUROC of 0.732, AUPRC of 0.187) was consistent with
29 previous studies (AUROC of 0.728 in a study conducted in the UK) [11].

30 For machine learning models with aggregate values, as we used summarized data for
31 physical and laboratory features, and we also included 40 additional pre-selected features
32 including diagnosis codes and medication codes, the performance of prediction was significantly

33 improved. Further, the min, max and SD values were ranked higher in importance than the
34 median values. BMI, medications (e.g. aspirin) that were not used by the ACC/AHA equations
35 were also present in the top 10 features.

36 Longitudinal information reflects the fluctuation of physiological factors over time,
37 which can be used for prediction models to enhance CVD risk prediction. The most recent results
38 from the STABILITY trial suggested the higher visit-to-visit variabilities of both systolic and
39 diastolic blood pressures are strong predictors of increased risk of CVD, independently of mean
40 blood pressure[28]. By zooming in the observation window of one-year slice time, we
41 constructed multivariate temporal features for machine learning models and deep learning
42 models. The results showed that it improved the prediction performance. CNN and LSTM that
43 allows for exhibiting dynamic temporal changes, outperformed LR and RF models. Surprisingly,
44 GBT almost had similar performance as LSTM and CNN. The time steps (7 years, 7-time steps)
45 may not be long enough to activate the gates of LSTM. Another reason is that a 10-year follow-
46 up prediction window may be a little long thereby removing the advantage of LSTM and CNN in
47 capturing the dependency with the observation and prediction.

48 Our approach also underscores the importance of including genetic variants. It has long
49 been known that CVD has a sizeable hereditary component [3], and emerging data continue to
50 increase our understanding of the genetic architecture underlying this important clinical trait
51 [20,21]. Previous studies have uncovered many novel genetic associations with CVD for risk
52 factors that are also heritable such as lipids, blood pressure, and diabetes [29,30]. While
53 polygenic scores have been used to summarize genetic effects for diseases, strategies to combine
54 genetic variants with other biological and lifestyle factors for existing predictive models remains

55 a topic of intense ongoing investigation. Although 10,162 individuals (2,452 cases and 7,710
56 controls) of our main study cohort had genotype data available, this subset may still limit our
57 power for large scale genetic analyses and machine learning. Since the quality of prediction often
58 depends on the amount of available training data, without sufficient training data, the learning
59 models cannot differentiate useful patterns from noise and predictive accuracy may
60 underperform. To overcome this challenge, we proposed a late-fusion approach to pre-train the
61 models with EHR features and genetic features separately by taking advantage of a larger
62 genotyped cohort (34,926).

63 From the results, we can see that adding genetic features offered benefit to clinical
64 features and significantly improved the performance compared to gold standard and only using
65 longitudinal EHR features.

66 **Importance of Genetic Features**

67 We present the top 10 features identified from the cohort (Supplementary Appendices S3).
68 Age remains the strongest predictor for CVD (coefficient 0.747), followed by gender, EHR
69 length and two variants from *MIA3* gene. Although dyslipidemia is one of the most important
70 risk factors for CVD, none of the top genes was strong predictor for circulating lipid levels,
71 except *LPA* gene.

72 While *LPA* genotype are associated with circulating lipid levels, it also strongly
73 influenced Lp(a) levels which was an independent CVD predictor with or without statin
74 treatment [31]. For decades, lipid-lowering medications (especially statins) have been shown to
75 be effective in both primary and secondary CVD prevention. Our observations highlight the

76 importance of CVD risk determinants independent of lipid levels. These findings underscore the
77 importance of targeting residual CVD risk through non-lipid mechanisms.

78 We acknowledge the limitations that, 1) we manually abstracted a subset of the physical
79 or laboratory features known to impact CVD risk, and we planned to incorporate more laboratory
80 features that could be automatically selected by feature engineering from the EHR, and 2) we
81 only used 204 SNPs in our study, whereas some of effects of the SNPs are modeled by
82 phenotypes (e.g., a SNPs affecting cholesterol are better captured by direct cholesterol
83 measurements). Yet some SNPs for *endophenotypes* are more predictive of CVD events than the
84 endophenotype itself [31]. As each SNP has a relatively small effect size compared with other
85 features like age, gender, and diabetes, and thus may not contribute much to the predictive ability
86 of the models, we believe that with more phenotypic and genetic information available in larger
87 cohorts may further improve prediction. This study confirmed that combining phenotypic and
88 genetic information with robust computational models can improve disease prediction.

89 **FUNDING**

90 The project was supported NIH grant P50 GM115305, R01 HL133786, R01 GM120523,
91 T32 GM007347 from the National Institute of General Medical Studies for the Vanderbilt
92 Medical-Scientist Training Program, and T15 LM007450 from the National Library of Medicine
93 for the Vanderbilt Biomedical Informatics Training Program.

94 The dataset used in the analyses described were obtained from Vanderbilt University
95 Medical Centers BioVU which is supported by institutional funding and by the CTSA grant

96 ULTR000445 from NCATS/NIH. Genome-wide genotyping was funded by NIH grants
97 RC2GM092618 from NIGMS/OD and U01HG004603 from NHGRI/NIGMS."

98 The dataset(s) used for the analyses described were obtained from Vanderbilt University
99 Medical Center's BioVU which is supported by institutional funding, the 1S10RR025141-01
100 instrumentation award, and by the CTSA grant UL1TR000445 from NCATS/NIH. The authors
101 wish to acknowledge the expert technical support of the VANTAGE and VANGARD core
102 facilities, supported in part by the Vanderbilt-Ingram Cancer Center (P30 CA068485) and
103 Vanderbilt Vision Center (P30 EY08126).

104 This study was supported by GM120523, GM109145, HL133786, 5T32GM080178-09,
105 K23AR064768, Rheumatology Research Foundation (K-supplement), American Heart
106 Association (16SDG27490014 and 15MCPRP25620006), HG008672, R01 LM010685,
107 GM115305 and Vanderbilt Faculty Research Scholar Fund. The dataset used for the analyses
108 described were obtained from Vanderbilt University Medical Center's resources, BioVU and the
109 Synthetic Derivative, which are supported by institutional funding and by the Vanderbilt
110 National Center for Advancing Translational Science grant 2UL1 TR000445-06 from
111 NCATS/NIH. Existing genotypes in BioVU were funded by NIH grants RC2GM092618 from
112 NIGMS/OD and U01HG004603 from NHGRI/NIGMS. The funders had no role in study design,
113 data collection and analysis, decision to publish, or preparation of the manuscript.

114 **COMPETING INTEREST**

115 The authors have no competing interests to declare.

116 REFERENCES

- 117 1 WHO | The top 10 causes of death. WHO.
118 doi:/entity/mediacentre/factsheets/fs310/en/index.html
- 119 2 Benjamin EJ, Blaha MJ, Chiuve SE, *et al.* Heart Disease and Stroke Statistics—2017 Update:
120 A Report From the American Heart Association. *Circulation* 2017;**135**:e146–603.
121 doi:10.1161/CIR.0000000000000485
- 122 3 D’Agostino RB, Vasan RS, Pencina MJ, *et al.* General Cardiovascular Risk Profile for Use
123 in Primary Care: The Framingham Heart Study. *Circulation* 2008;**117**:743–753.
124 doi:10.1161/CIRCULATIONAHA.107.699579
- 125 4 Goff DC, Lloyd-Jones DM, Bennett G, *et al.* 2013 ACC/AHA Guideline on the Assessment
126 of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart
127 Association Task Force on Practice Guidelines. *Circulation* 2013;**63**:2935–59.
128 doi:10.1161/01.cir.0000437741.48606.98
- 129 5 Hippisley-Cox J, Coupland C, Vinogradova Y, *et al.* Predicting cardiovascular risk in
130 England and Wales: prospective derivation and validation of QRISK2. *BMJ* 2008;**336**:1475–
131 1482. doi:10.1136/bmj.39609.449676.25
- 132 6 Kannel WB, Vasan RS. Adverse consequences of the 50% misconception. *Am J Cardiol*
133 2009;**103**:426–7. doi:10.1016/j.amjcard.2008.09.098
- 134 7 Khot UN. Prevalence of Conventional Risk Factors in Patients With Coronary Heart Disease.
135 *JAMA* 2003;**290**:898. doi:10.1001/jama.290.7.898
- 136 8 Wei W-Q, Denny JC. Extracting research-quality phenotypes from electronic health records
137 to support precision medicine. *Genome Med* 2015;**7**. doi:10.1186/s13073-015-0166-y
- 138 9 Choi E, Schuetz A, Stewart WF, *et al.* Using recurrent neural network models for early
139 detection of heart failure onset. *Journal of the American Medical Informatics Association*
140 2017;**24**:361–70. doi:10.1093/jamia/ocw112
- 141 10 Singh A, Nadkarni G, Gottesman O, *et al.* Incorporating temporal EHR data in predictive
142 models for risk stratification of renal function deterioration. *Journal of Biomedical*
143 *Informatics* 2015;**53**:220–8. doi:10.1016/j.jbi.2014.11.005
- 144 11 Weng SF, Reys J, Kai J, *et al.* Can machine-learning improve cardiovascular risk prediction
145 using routine clinical data? *PLOS ONE* 2017;**12**:1–14. doi:10.1371/journal.pone.0174944
- 146 12 Schildcrout JS, Denny JC, Bowton E, *et al.* Optimizing drug outcomes through
147 pharmacogenetics: A case for preemptive genotyping. *Clin Pharmacol Ther* 2012;**92**:235–42.
148 doi:10.1038/clpt.2012.66

- 149 13 Wei W-Q, Leibson CL, Ransom JE, *et al.* Impact of data fragmentation across healthcare
150 centers on the accuracy of a high-throughput clinical phenotyping algorithm for specifying
151 subjects with type 2 diabetes mellitus. *Journal of the American Medical Informatics*
152 *Association* 2012;**19**:219–24. doi:10.1136/amiajnl-2011-000597
- 153 14 Wei W-Q, Leibson CL, Ransom JE, *et al.* The absence of longitudinal data limits the
154 accuracy of high-throughput clinical phenotyping for identifying type 2 diabetes mellitus
155 subjects. *Int J Med Inform* 2013;**82**:239–47. doi:10.1016/j.ijmedinf.2012.05.015
- 156 15 Liu H, Setiono R. Chi2: feature selection and discretization of numeric attributes. In:
157 *Proceedings of 7th IEEE International Conference on Tools with Artificial Intelligence*. 1995.
158 388–91. doi:10.1109/TAI.1995.479783
- 159 16 Yackel TR, Embi PJ. Unintended errors with EHR-based result management: a case series. *J*
160 *Am Med Inform Assoc* 2010;**17**:104–7. doi:10.1197/jamia.M3294
- 161 17 Batista GEAPA, Monard MC. An analysis of four missing data treatment methods for
162 supervised learning. *Applied Artificial Intelligence* 2003;**17**:519–33. doi:10.1080/713827181
- 163 18 Wei W-Q, Bastarache LA, Carroll RJ, *et al.* Evaluating phecodes, clinical classification
164 software, and ICD-9-CM codes for phenome-wide association studies in the electronic health
165 record. *PLOS ONE* 2017;**12**:1–16. doi:10.1371/journal.pone.0175508
- 166 19 Normalized names for clinical drugs: RxNorm at 6 years.
167 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3128404/> (accessed 18 May 2018).
- 168 20 Khera AV, Emdin CA, Drake I, *et al.* Genetic Risk, Adherence to a Healthy Lifestyle, and
169 Coronary Disease. *New England Journal of Medicine* 2016;**375**:2349–58.
170 doi:10.1056/NEJMoa1605086
- 171 21 Paquette M, Chong M, Thériault S, *et al.* Polygenic risk score predicts prevalence of
172 cardiovascular disease in patients with familial hypercholesterolemia. *Journal of Clinical*
173 *Lipidology* 2017;**11**:725–732.e5. doi:10.1016/j.jacl.2017.03.019
- 174 22 LeCun Y, Bengio Y, Hinton G. Deep learning. *Nature* 2015;**521**:436–44.
175 doi:10.1038/nature14539
- 176 23 Hochreiter S, Schmidhuber J. Long short-term memory. *Neural Comput* 1997;**9**:1735–80.
- 177 24 Pedregosa F, Varoquaux G, Gramfort A, *et al.* Scikit-learn: Machine Learning in Python. *J*
178 *Mach Learn Res* 2011;**12**:2825–2830.
- 179 25 Saito T, Rehmsmeier M. The Precision-Recall Plot Is More Informative than the ROC Plot
180 When Evaluating Binary Classifiers on Imbalanced Datasets. *PLOS ONE* 2015;**10**:e0118432.
181 doi:10.1371/journal.pone.0118432
- 182 26 Lai KT, Liu D, Chang SF, *et al.* Learning Sample Specific Weights for Late Fusion. *IEEE*
183 *Transactions on Image Processing* 2015;**24**:2772–83. doi:10.1109/TIP.2015.2423560

- 184 27 Tillin T, Hughes AD, Whincup P, *et al.* Ethnicity and prediction of cardiovascular disease:
185 performance of QRISK2 and Framingham scores in a U.K. tri-ethnic prospective cohort
186 study (SABRE--Southall And Brent REvisited). *Heart* 2014;**100**:60–7. doi:10.1136/heartjnl-
187 2013-304474
- 188 28 Vidal-Petiot E, Stebbins A, Chiswell K, *et al.* Visit-to-visit variability of blood pressure and
189 cardiovascular outcomes in patients with stable coronary heart disease. Insights from the
190 STABILITY trial. *Eur Heart J* 2017;**38**:2813–22. doi:10.1093/eurheartj/ehx250
- 191 29 Gaulton KJ, Ferreira T, Lee Y, *et al.* Genetic fine mapping and genomic annotation defines
192 causal mechanisms at type 2 diabetes susceptibility loci. *Nat Genet* 2015;**47**:1415–25.
193 doi:10.1038/ng.3437
- 194 30 McCarthy MI. Genomics, Type 2 Diabetes, and Obesity. *New England Journal of Medicine*
195 2010;**363**:2339–50. doi:10.1056/NEJMra0906948
- 196 31 Wei W-Q, Li X, Feng Q, *et al.* *LPA* Variants are Associated with Residual Cardiovascular
197 Risk in Patients Receiving Statins. *Circulation* 2018;:CIRCULATIONAHA.117.031356.
198 doi:10.1161/CIRCULATIONAHA.117.031356

199

200 Figure Legends

201 Figure 1. Flowchart of Experiment I: comparison of machine learning and deep learning
202 models on longitudinal features against baselines.

203

204

205 Figure 2. Flowchart of selecting cohort for late-fusion approach

206 Figure 3. Framework for proposed late fusion approach to combine the genetic features
207 with longitudinal EHR features.

208

VUMC EHR Cohort > 3 million

Criteria

- $18 \leq \text{Age} \leq 78$ at 01/01/2000
- European or African ancestry
- ≥ 1 blood pressure and ≥ 1 visits in the observation window
- No CVD history

Study cohort (n = 109,490)

Case (n = 9,824) : Control (n = 99,666)
= 1 : 10.2
Age: 47.4 ± 14.7

Gold Standard- ACC/ AHA Pooled Cohort Risk Equations

Extract most recent value (before 01/01/2007)

Demographic + aggregate values
aggregate labs + diagnosis
(phecode) + medication across the
observation window

Logistic
regression,
random forest,
Gradient
boosting trees

Demographic + longitudinal values (Multivariate temporal)

t_0 t_1 ... t_i

 X_0 ... X_m X_0 ... X_m X_m

Logistic
regression,
random forest,
Gradient
boosting trees

labs diagnosis medication

 t_0 X_0 X_1 X_2 ... X_m
 t_1
...
 t_i

CNN, LSTM

VUMC SD >3 million

Main study cohort
from EHRs
n = 109,490


**Big
genotyped
cohort**
n= 34, 926

Intersect cohort
n=10,162

**Training cohort
for fusion**
n=8,129

Holdout test
n=2,033

Stage 1



Stage 2

